T1	Participants 370 492	patients with symptomatic, smoking-related COPD, randomized to receive sibenadet or placebo for a 52-week treatment period
T2	Participants 39 90	patients with chronic obstructive pulmonary disease
T3	Participants 1380 1437	patients with severe COPD (stage III) than mild (stage I)
T4	Participants 2046 2062	elderly patients
